AGING CELL:男性Y染色体年龄依赖性DNA甲基化模式

2019-03-01 海北 MedSci原创

衰老相关表型和死亡率的性别差异可能表明,性染色体在衰老过程中起着关键作用。

由于多种原因,Y染色体是一种仅存在于雄性中的性染色体,其在传统的表观遗传学关联研究中常常被忽略。然而,衰老相关表型和死亡率的性别差异可能表明,性染色体在衰老过程中起着关键作用。

最近,研究人员获得了来自四个队列的624名男性的基于血液的Y染色体DNA甲基化数据,并进行了染色体范围的表观遗传关联分析,以检测在年龄上差异甲基化的Y连锁CpG,并交叉验证了四个队列中的显着CpG。

研究人员鉴定了40-219个显着的CpG位点(错误发现率<0.05),其中> 82%的高甲基化随着年龄增加而发生,这与常染色体上报道的模式形成强烈对比。

比较代表不同年龄间隔的群组中Y连锁DNA甲基化的变化率揭示了随着年龄增加DNA甲基化加速的趋势。

进一步检查Y染色体上与年龄相关的DNA甲基化模式与全因死亡率的关系,研究人员发现Y染色体上与年龄相关的高甲基化的主要模式与降低的死亡风险相关。


原始出处:

Jesper B. Lund et al. Age‐dependent DNA methylation patterns on the Y chromosome in elderly males. Aging Cell, 2019; doi: https://doi.org/10.1111/acel.12907


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1961451, encodeId=bbcb1961451fe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 30 21:07:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871173, encodeId=162618e11735a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Dec 19 12:07:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331703, encodeId=21031331e03f0, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Sat Mar 02 23:07:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538852, encodeId=dd3715388529f, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Sat Mar 02 23:07:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361762, encodeId=5dd5361e629a, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Fri Mar 01 08:18:18 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2019-12-30 医者仁心
  2. [GetPortalCommentsPageByObjectIdResponse(id=1961451, encodeId=bbcb1961451fe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 30 21:07:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871173, encodeId=162618e11735a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Dec 19 12:07:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331703, encodeId=21031331e03f0, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Sat Mar 02 23:07:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538852, encodeId=dd3715388529f, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Sat Mar 02 23:07:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361762, encodeId=5dd5361e629a, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Fri Mar 01 08:18:18 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1961451, encodeId=bbcb1961451fe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 30 21:07:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871173, encodeId=162618e11735a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Dec 19 12:07:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331703, encodeId=21031331e03f0, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Sat Mar 02 23:07:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538852, encodeId=dd3715388529f, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Sat Mar 02 23:07:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361762, encodeId=5dd5361e629a, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Fri Mar 01 08:18:18 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1961451, encodeId=bbcb1961451fe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 30 21:07:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871173, encodeId=162618e11735a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Dec 19 12:07:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331703, encodeId=21031331e03f0, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Sat Mar 02 23:07:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538852, encodeId=dd3715388529f, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Sat Mar 02 23:07:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361762, encodeId=5dd5361e629a, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Fri Mar 01 08:18:18 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2019-03-02 周虎
  5. [GetPortalCommentsPageByObjectIdResponse(id=1961451, encodeId=bbcb1961451fe, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 30 21:07:00 CST 2019, time=2019-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871173, encodeId=162618e11735a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Dec 19 12:07:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331703, encodeId=21031331e03f0, content=<a href='/topic/show?id=d85a6181e4d' target=_blank style='color:#2F92EE;'>#染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61817, encryptionId=d85a6181e4d, topicName=染色体)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Sat Mar 02 23:07:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538852, encodeId=dd3715388529f, content=<a href='/topic/show?id=9f5a189918d' target=_blank style='color:#2F92EE;'>#Y染色体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18991, encryptionId=9f5a189918d, topicName=Y染色体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1fc213064778, createdName=周虎, createdTime=Sat Mar 02 23:07:00 CST 2019, time=2019-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361762, encodeId=5dd5361e629a, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqYPFHuMA3bhYQrHvycmum7IJoCsLK0FP6X56Eoj9PZAECDke8zLCKxZZvk9q7B6rZmPuFgN5YCfw/132, createdBy=f52d2514454, createdName=SCI我的梦, createdTime=Fri Mar 01 08:18:18 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2019-03-01 SCI我的梦

    谢谢分享

    0

相关资讯

JCEM:青春期BMI变化是男性成人2型糖尿病风险的重要决定因素

由此可见,青春期BMI变化是男性成人2型糖尿病风险一个重要的,而儿童BMI是一个中等的独立决定因素。

Neurology:男性长期摄入蔬菜和水果与主观认知功能

由此可见,该研究结果支持蔬菜、水果和橙汁摄入对SCF的长期有益作用。

Int J Impot Res:低强度体外震波疗法治疗阴茎勃起功能障碍的临床研究

低强度体外震波疗法治疗(LI-ESWT)在治疗阴茎勃起功能障碍(ED)方面的效果已经具有严格的评判,并且最近报道的元分析也并没有提供进一步的认知或者具体的建议。最近,有研究人员进行了系统的回顾和元分析来评估LI-ESWT对ED的治疗效果,并且尝试确定理想的治疗群体和治疗方法,并且为该领域的研究提供具体的建议。研究人员对公布的2010年1月到2018年9月相关的临床研究进行了系统的分析,他们的研究只

Alzheimers Dement:男性听力损失和主观认知功能减退的纵向研究

最近,有研究人员调查了自我报道的听力损失、助听器使用和主观认知功能(SCF)减退风险之间的相关性。研究人员进行了为期8年(2008-2016)的纵向研究,包括了10107名年龄不小于62岁且报道听力状态的男性,且他们在2008年没有主观认知忧虑。研究人员利用包括6个条目的调查问卷对SCF得分的变化进行了评估。研究发现,听力损失与更高风险的SCF减退风险相关。与没有听力损失相比,在轻度、中度和重度听

中年男性多发性髓石一例

髓石一直以来被认为是牙髓病理性钙化的产物,多由炎症或牙髓老龄化状态等因素引起,多数无症状,偶有急性牙髓炎表现、三叉神经样疼痛或偏头痛等有症状髓石报道,而健康牙无症状髓石较少。本文将报道健康成年人无症状多发性髓石一例,并就相关文献对其病因及机制进行分析。

JAMA Oncol:激素受体阳性男性乳腺癌的辅助内分泌治疗应用现状及疗效观察

男性乳腺癌非常少见,因此缺少大宗临床研究数据,治疗推荐多由女性乳腺癌外推而来。多数男性乳腺癌为激素受体阳性,内分泌治疗是很重要的治疗组成。内分泌治疗在女性乳腺癌辅助治疗时有生存获益,那么对于激素受体阳性的男性乳腺癌患者而言也是一样的结果吗?近期《JAMA Oncology》刊登了一篇来源于宾夕法尼亚大学佩雷尔曼医学院放射肿瘤学系专家的文章。对激素受体阳性的男性乳腺癌患者使用辅助内分泌治疗的应用现状